{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,15]],"date-time":"2025-07-15T03:34:26Z","timestamp":1752550466374},"reference-count":173,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2006,4,1]],"date-time":"2006-04-01T00:00:00Z","timestamp":1143849600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2006,4]]},"DOI":"10.4065\/81.4.553","type":"journal-article","created":{"date-parts":[[2009,1,24]],"date-time":"2009-01-24T01:27:47Z","timestamp":1232760467000},"page":"553-563","source":"Crossref","is-referenced-by-count":39,"title":["Atypical Myeloproliferative Disorders: Diagnosis and Management"],"prefix":"10.4065","volume":"81","author":[{"given":"Ayalew","family":"Tefferi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michelle A.","family":"Elliott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Animesh","family":"Pardanani","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/81.4.553_bib1","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1182\/blood.V6.4.372.372","article-title":"Some speculations on the myeloproliferative syndromes","volume":"6","author":"Dameshek","year":"1951","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib2","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1182\/blood-2002-04-1199","article-title":"The World Health Organization (WHO) classification of the myeloid neoplasms","volume":"100","author":"Vardiman","year":"2002","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib3","doi-asserted-by":"crossref","first-page":"947","DOI":"10.4065\/80.7.947","article-title":"The JAK2V617F tyrosine kinase mutation in myeloproliferative disorders: status report and immediate implications for disease classification and diagnosis","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.4.553_bib4","first-page":"3","article-title":"Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia","volume":"36","author":"Tefferi","year":"1999","journal-title":"Semin Hematol"},{"key":"10.4065\/81.4.553_bib5","unstructured":"Tefferi A, Gilliland DG. Classification of myeloproliferative disorders: from Dameshek towards a semi-molecular system. Baillieres Best Pract Res Clin Haematol. In press."},{"key":"10.4065\/81.4.553_bib6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0025-6196(11)62962-5","article-title":"Blood eosinophilia: a new paradigm in disease classification, diagnosis, and treatment","volume":"80","author":"Tefferi","year":"2005","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.4.553_bib7","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0165-4608(89)90137-4","article-title":"Acute myelogenous leukemia (FAB M1) associated with t(5;16) and eosinophilia: report of an additional case","volume":"43","author":"Sanada","year":"1989","journal-title":"Cancer Genet Cytogenet"},{"key":"10.4065\/81.4.553_bib8","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1182\/blood.V44.4.489.489","article-title":"Loffler's endomyocardial fibrosis with eosinophilia in association with acute lymphoblastic leukemia","volume":"44","author":"Blatt","year":"1974","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib9","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0165-4608(02)00609-X","article-title":"Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature","volume":"138","author":"Keung","year":"2002","journal-title":"Cancer Genet Cytogenet"},{"key":"10.4065\/81.4.553_bib10","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1159\/000039744","article-title":"Myelodysplastic syndrome with clonal eosinophilia accompanied by eosinophilic pulmonary interstitial infiltration","volume":"104","author":"Kuroda","year":"2000","journal-title":"Acta Haematol"},{"key":"10.4065\/81.4.553_bib11","doi-asserted-by":"crossref","first-page":"4187","DOI":"10.1182\/blood-2003-04-1150","article-title":"Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib","volume":"102","author":"Wilkinson","year":"2003","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib12","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1046\/j.1365-2141.2003.04458.x","article-title":"Cytogenetic and molecular genetic aspects of eosinophilic leukaemias","volume":"122","author":"Bain","year":"2003","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib13","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1056\/NEJMoa025217","article-title":"A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome","volume":"348","author":"Cools","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4065\/81.4.553_bib14","doi-asserted-by":"crossref","first-page":"3093","DOI":"10.1182\/blood-2003-05-1627","article-title":"CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib therapy","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib15","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJMoa020150","article-title":"Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta","volume":"347","author":"Apperley","year":"2002","journal-title":"N Engl J Med"},{"key":"10.4065\/81.4.553_bib16","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1038\/sj.leu.2402556","article-title":"Tyrosine kinase fusion genes in chronic myeloproliferative diseases","volume":"16","author":"Cross","year":"2002","journal-title":"Leukemia"},{"key":"10.4065\/81.4.553_bib17","doi-asserted-by":"crossref","first-page":"5702","DOI":"10.1038\/sj.onc.1206543","article-title":"Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571\/Glivec","volume":"22","author":"Trempat","year":"2003","journal-title":"Oncogene"},{"key":"10.4065\/81.4.553_bib18","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1093\/hmg\/11.12.1391","article-title":"The t(4;22)(q12;q11) in atypical chronic myeloid leukaemia fuses BCR to PDGFRA","volume":"11","author":"Baxter","year":"2002","journal-title":"Hum Mol Genet"},{"key":"10.4065\/81.4.553_bib19","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1002\/gcc.20014","article-title":"Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia","volume":"40","author":"Safley","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"10.4065\/81.4.553_bib20","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1016\/S1535-6108(03)00108-9","article-title":"PKC412 overcomes resistance to imatinib in a murine model of FIP1L1-PDGFRalpha-induced myeloproliferative disease","volume":"3","author":"Cools","year":"2003","journal-title":"Cancer Cell"},{"key":"10.4065\/81.4.553_bib21","doi-asserted-by":"crossref","first-page":"7830","DOI":"10.1073\/pnas.0932698100","article-title":"Discovery of a fusion kinase in EOL-1 cells and idiopathic hypereosinophilic syndrome","volume":"100","author":"Griffin","year":"2003","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4065\/81.4.553_bib22","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1182\/blood-2004-03-0787","article-title":"FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia","volume":"104","author":"Pardanani","year":"2004","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib23","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1038\/sj.leu.2403313","article-title":"Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias","volume":"18","author":"Vandenberghe","year":"2004","journal-title":"Leukemia"},{"key":"10.4065\/81.4.553_bib24","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1182\/blood-2003-08-2798","article-title":"Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib25","first-page":"146a","article-title":"FIP1L1-PDGFRA fusion in eosinophilia-associated disorders: prevalence and clinicopathologic correlates [abstract]","volume":"102","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib26","first-page":"100","article-title":"Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative","volume":"56","author":"Buchdunger","year":"1996","journal-title":"Cancer Res"},{"key":"10.4065\/81.4.553_bib27","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.leu.2403329","article-title":"Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis","volume":"18","author":"Elliott","year":"2004","journal-title":"Leukemia"},{"key":"10.4065\/81.4.553_bib28","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0002-9343(03)00475-3","article-title":"Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib","volume":"115","author":"Koury","year":"2003","journal-title":"Am J Med"},{"key":"10.4065\/81.4.553_bib29","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1016\/j.euje.2004.02.006","article-title":"Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor","volume":"5","author":"Ascione","year":"2004","journal-title":"Eur J Echocardiogr"},{"key":"10.4065\/81.4.553_bib30","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2002-10-3103","article-title":"Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders","volume":"101","author":"Pardanani","year":"2003","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib31","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1159\/000046641","article-title":"Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor beta","volume":"107","author":"Steer","year":"2002","journal-title":"Acta Haematol"},{"key":"10.4065\/81.4.553_bib32","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1159\/000046640","article-title":"Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach: a case report","volume":"107","author":"Granjo","year":"2002","journal-title":"Acta Haematol"},{"key":"10.4065\/81.4.553_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2141.2002.03469.x","article-title":"Receptor tyrosine kinase mutations in myeloid neoplasms","volume":"117","author":"Gupta","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib34","doi-asserted-by":"crossref","first-page":"4271","DOI":"10.1182\/blood.V90.11.4271","article-title":"Fusion of the platelet-derived growth factor receptor beta to a novel gene CEV14 in acute myelogenous leukemia after clonal evolution","volume":"90","author":"Abe","year":"1997","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib35","first-page":"ECR18","article-title":"Response to STI571 in chronic myelomonocytic leukemia with platelet derived growth factor beta receptor involvement: a new case report","volume":"88","author":"Pitini","year":"2003","journal-title":"Haematologica"},{"key":"10.4065\/81.4.553_bib36","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1182\/blood-2002-01-0165","article-title":"Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene","volume":"100","author":"Magnusson","year":"2002","journal-title":"Blood"},{"issue":"suppl 1","key":"10.4065\/81.4.553_bib37","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.leukres.2003.10.011","article-title":"A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate","volume":"28","author":"Wittman","year":"2004","journal-title":"Leuk Res"},{"key":"10.4065\/81.4.553_bib38","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.cancergencyto.2004.01.013","article-title":"Prevalence, breakpoint distribution, and clinical correlates of t(5;12)","volume":"153","author":"Greipp","year":"2004","journal-title":"Cancer Genet Cytogenet"},{"key":"10.4065\/81.4.553_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2005.11.011","article-title":"FIP1L1-PDGFRA in eosinophilic disorders: prevalence in routine clinical practice, long-term experience with imatinib therapy, and a critical review of the literature","author":"Pardanani","year":"2006","journal-title":"Leuk Res"},{"key":"10.4065\/81.4.553_bib40","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1159\/000046639","article-title":"The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1","volume":"107","author":"Macdonald","year":"2002","journal-title":"Acta Haematol"},{"key":"10.4065\/81.4.553_bib41","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/sj.leu.2403712","article-title":"The t(8;17)(p11;q23) in the 8p11 myeloproliferative syndrome fuses MYO18A to FGFR1","volume":"19","author":"Walz","year":"2005","journal-title":"Leukemia"},{"key":"10.4065\/81.4.553_bib42","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1182\/blood-2003-11-3816","article-title":"A novel form of mastocytosis associated with a transmembrane c-kit mutation and response to imatinib","volume":"103","author":"Akin","year":"2004","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib43","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1038\/ng0396-312","article-title":"Somatic c-KIT activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm","volume":"12","author":"Longley","year":"1996","journal-title":"Nat Genet"},{"key":"10.4065\/81.4.553_bib44","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1046\/j.1365-2141.1997.d01-2042.x","article-title":"A new c-kit mutation in a case of aggressive mast cell disease","volume":"96","author":"Pignon","year":"1997","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib45","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S0145-2126(02)00303-X","article-title":"Flt-3 and c-kit mutation studies in a spectrum of chronic myeloid disorders including systemic mast cell disease","volume":"27","author":"Pardanani","year":"2003","journal-title":"Leuk Res"},{"key":"10.4065\/81.4.553_bib46","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1046\/j.1523-1747.1998.00414.x","article-title":"Identification of activating c-kit mutations in adult-, but not in childhood-onset indolent mastocytosis: a possible explanation for divergent clinical behavior","volume":"111","author":"Buttner","year":"1998","journal-title":"J Invest Dermatol"},{"key":"10.4065\/81.4.553_bib47","doi-asserted-by":"crossref","first-page":"10560","DOI":"10.1073\/pnas.92.23.10560","article-title":"Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder","volume":"92","author":"Nagata","year":"1995","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.4065\/81.4.553_bib48","doi-asserted-by":"crossref","first-page":"1741","DOI":"10.1182\/blood.V99.5.1741","article-title":"The c-KIT mutation causing human mastocytosis is resistant to STI571 and other KIT kinase inhibitors; kinases with enzymatic site mutations show different inhibitor sensitivity profiles than wild-type kinases and those with regulatory-type mutations","volume":"99","author":"Ma","year":"2002","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib49","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1038\/sj.onc.1206120","article-title":"Effect of tyrosine kinase inhibitor STI571 on the kinase activity of wild-type and various mutated c-kit receptors found in mast cell neoplasms","volume":"22","author":"Zermati","year":"2003","journal-title":"Oncogene"},{"key":"10.4065\/81.4.553_bib50","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S0301-472X(03)00112-7","article-title":"Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit","volume":"31","author":"Akin","year":"2003","journal-title":"Exp Hematol"},{"key":"10.4065\/81.4.553_bib51","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1046\/j.1365-2141.2002.03944.x","article-title":"Treatment of adult systemic mastocytosis with interferon-alpha: results of a multicentre phase II trial on 20 patients","volume":"119","author":"Casassus","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1046\/j.1365-2133.1998.02131.x","article-title":"Response of severe systemic mastocytosis to interferon alpha","volume":"138","author":"Butterfield","year":"1998","journal-title":"Br J Dermatol"},{"key":"10.4065\/81.4.553_bib53","first-page":"197","article-title":"Systemic mastocytosis: current concepts and treatment advances","volume":"3","author":"Tefferi","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"10.4065\/81.4.553_bib54","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2005-10-3969","article-title":"Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in the majority of patients with systemic mastocytosis","author":"Shah","year":"2006","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib55","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1038\/sj.leu.2403562","article-title":"WHO-defined chronic neutrophilic leukemia: a long-term analysis of 12 cases and a critical review of the literature","volume":"19","author":"Elliott","year":"2005","journal-title":"Leukemia"},{"key":"10.4065\/81.4.553_bib56","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/ajcp\/72.2.233","article-title":"Chronic neutrophilic leukemia: report of two cases and review of the literature","volume":"72","author":"You","year":"1979","journal-title":"Am J Clin Pathol"},{"key":"10.4065\/81.4.553_bib57","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1046\/j.1365-2141.2002.03234.x","article-title":"Chronic neutrophilic leukaemia: a distinct clinical entity?","volume":"116","author":"Reilly","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib58","series-title":"World Health Organization Classification of Tumours: Pathology and Genetics of Tumours and Lymphoid Tissue","year":"2001"},{"key":"10.4065\/81.4.553_bib59","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1136\/jcp.56.4.292","article-title":"Evidence of clonality in chronic neutrophilic leukaemia","volume":"56","author":"Bohm","year":"2003","journal-title":"J Clin Pathol"},{"key":"10.4065\/81.4.553_bib60","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1016\/S0950-3536(98)80041-3","article-title":"Molecular genetics and cytogenetics of myeloproliferative disorders","volume":"11","author":"Bench","year":"1998","journal-title":"Baillieres Clin Haematol"},{"key":"10.4065\/81.4.553_bib61","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.1182\/blood.V89.6.2079","article-title":"International scoring system for evaluating prognosis in myelodysplastic syndromes","volume":"89","author":"Greenberg","year":"1997","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib62","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1182\/blood.V92.7.2322","article-title":"The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial","volume":"92","author":"Grimwade","year":"1998","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib63","doi-asserted-by":"crossref","first-page":"2399","DOI":"10.1002\/1097-0142(20011101)92:9<2399::AID-CNCR1588>3.0.CO;2-W","article-title":"Tumor-related leukocytosis is linked with poor prognosis in patients with lung carcinoma","volume":"92","author":"Kasuga","year":"2001","journal-title":"Cancer"},{"key":"10.4065\/81.4.553_bib64","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.2003.21.1.168","article-title":"Uncommon syndromes and treatment manifestations of malignancy: case 2: metastatic non-small-cell lung cancer presenting with leukocytosis","volume":"21","author":"Ganti","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.4.553_bib65","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000205176","article-title":"Chronic neutrophilic leukaemia preceding for seven years the development of multiple myeloma","volume":"83","author":"Rovira","year":"1990","journal-title":"Acta Haematologica"},{"key":"10.4065\/81.4.553_bib66","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1002\/1097-0142(19900701)66:1<162::AID-CNCR2820660129>3.0.CO;2-Z","article-title":"Chronic neutrophilic leukemia and multiple myeloma: an association with lambda light chain expression","volume":"66","author":"Standen","year":"1990","journal-title":"Cancer"},{"key":"10.4065\/81.4.553_bib67","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1136\/jcp.46.4.297","article-title":"Clonality of chronic neutrophilic leukaemia associated with myeloma: analysis using the X-linked probe M27 beta","volume":"46","author":"Standen","year":"1993","journal-title":"J Clin Pathol"},{"key":"10.4065\/81.4.553_bib68","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1002\/(SICI)1096-8652(199809)59:1<79::AID-AJH15>3.0.CO;2-X","article-title":"Analysis of clonality using X-linked polymorphisms in a patient with multiple myeloma and myelofibrosis","volume":"59","author":"Stevenson","year":"1998","journal-title":"Am J Hematol"},{"key":"10.4065\/81.4.553_bib69","unstructured":"Imbert M, Vardiman JW, Pierre R, et al. Essential thrombocythemia. World Health Organization Classification of Tumours: Pathology and Genetics of Tumours and Lymphoid Tissue. Lyon, France: 2001:39\u201341."},{"key":"10.4065\/81.4.553_bib70","doi-asserted-by":"crossref","first-page":"2410","DOI":"10.1182\/blood.V88.7.2410.bloodjournal8872410","article-title":"Neutrophilic-chronic myeloid leukemia: a distinct disease with a specific molecular marker (BCR\/ABL with C3\/A2 junction) [published correction appears in Blood. 1997;89:4244]","volume":"88","author":"Pane","year":"1996","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib71","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1046\/j.1365-2141.1996.7082329.x","article-title":"Chronic neutrophil leukaemia in adolescence and young adulthood","volume":"94","author":"Hasle","year":"1996","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib72","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1002\/ajh.2830430416","article-title":"Successful alpha-2b-interferon therapy for chronic neutrophilic leukemia","volume":"43","author":"Meyer","year":"1993","journal-title":"Am J Hematol"},{"key":"10.4065\/81.4.553_bib73","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/sj.leu.2401993","article-title":"Chronic neutrophilic leukemia (CNL): a long-term clinical, pathologic, and cytogenetic study","volume":"15","author":"Elliott","year":"2001","journal-title":"Leukemia"},{"key":"10.4065\/81.4.553_bib74","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1136\/jcp.55.11.862","article-title":"Chronic neutrophilic leukaemia: 14 new cases of an uncommon myeloproliferative disease","volume":"55","author":"Bohm","year":"2002","journal-title":"J Clin Pathol"},{"key":"10.4065\/81.4.553_bib75","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1080\/1042819021000016087","article-title":"Allogeneic bone marrow transplantation in the management of chronic neutrophilic leukemia","volume":"43","author":"Piliotis","year":"2002","journal-title":"Leuk Lymphoma"},{"key":"10.4065\/81.4.553_bib76","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1002\/ajh.20088","article-title":"Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis","volume":"77","author":"Bain","year":"2004","journal-title":"Am J Hematol"},{"key":"10.4065\/81.4.553_bib77","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1046\/j.1365-2141.2003.04195.x","article-title":"The eosinophilias, including the idiopathic hypereosinophilic syndrome","volume":"121","author":"Brito-Babapulle","year":"2003","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib78","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S0165-4608(98)00099-5","article-title":"Chronic eosinophilic leukemia and hypereosinophilic syndromes: proposal for classification, literature review, and report of a case with a unique chromosomal abnormality","volume":"107","author":"Oliver","year":"1998","journal-title":"Cancer Genet Cytogenet"},{"key":"10.4065\/81.4.553_bib79","series-title":"World Health Organization Classification of Tumours: Tumours of the Haematopoietic and Lymphoid Tissues","first-page":"29","article-title":"Chronic eosinophilic leukemia and the hypereosinophilic syndrome","author":"Bain","year":"2001"},{"key":"10.4065\/81.4.553_bib80","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-197501000-00001","article-title":"The hypereosinophilic syndrome: analysis of fourteen cases with review of the literature","volume":"54","author":"Chusid","year":"1975","journal-title":"Medicine (Baltimore)"},{"key":"10.4065\/81.4.553_bib81","doi-asserted-by":"crossref","first-page":"78","DOI":"10.7326\/0003-4819-97-1-78","article-title":"NIH conference: the idiopathic hypereosinophilic syndrome: clinical, pathophysiologic, and therapeutic considerations","volume":"97","author":"Fauci","year":"1982","journal-title":"Ann Intern Med"},{"key":"10.4065\/81.4.553_bib82","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJM198406213102501","article-title":"Episodic angioedema associated with eosinophilia","volume":"310","author":"Gleich","year":"1984","journal-title":"N Engl J Med"},{"key":"10.4065\/81.4.553_bib83","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1182\/blood-2003-01-0006","article-title":"Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness","volume":"101","author":"Klion","year":"2003","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib84","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1046\/j.1365-2141.2000.02097.x","article-title":"Clonal Th2 lymphocytes in patients with the idiopathic hypereosinophilic syndrome","volume":"109","author":"Roufosse","year":"2000","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib85","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1056\/NEJM200005253422104","article-title":"Eosinophilia with aberrant T cells and elevated serum levels of interleukin-2 and interleukin-15","volume":"342","author":"Means-Markwell","year":"2000","journal-title":"N Engl J Med"},{"key":"10.4065\/81.4.553_bib86","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/0002-9149(83)90131-5","article-title":"Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome","volume":"52","author":"Harley","year":"1983","journal-title":"Am J Cardiol"},{"key":"10.4065\/81.4.553_bib87","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.jaci.2003.10.049","article-title":"Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes","volume":"113","author":"Garrett","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.4065\/81.4.553_bib88","doi-asserted-by":"crossref","first-page":"167","DOI":"10.7326\/0003-4819-89-2-167","article-title":"Therapy of the hypereosinophilic syndrome","volume":"89","author":"Parrillo","year":"1978","journal-title":"Ann Intern Med"},{"key":"10.4065\/81.4.553_bib89","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1182\/blood.V58.5.1021.1021","article-title":"A clinicopathologic correlation of the idiopathic hypereosinophilic syndrome, II: clinical manifestations","volume":"58","author":"Schooley","year":"1981","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib90","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1111\/j.1365-2141.1990.tb07811.x","article-title":"Alfa-interferon in a case of hypereosinophilic syndrome","volume":"75","author":"Murphy","year":"1990","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib91","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1159\/000204495","article-title":"Sustained remission of idiopathic hypereosinophilic syndrome following alpha-interferon therapy","volume":"89","author":"Fruehauf","year":"1993","journal-title":"Acta Haematol"},{"key":"10.4065\/81.4.553_bib92","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1016\/0091-6749(94)90348-4","article-title":"Response of six patients with idiopathic hypereosinophilic syndrome to interferon alfa","volume":"94","author":"Butterfield","year":"1994","journal-title":"J Allergy Clin Immunol"},{"key":"10.4065\/81.4.553_bib93","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s002770050434","article-title":"Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases","volume":"77","author":"Ceretelli","year":"1998","journal-title":"Ann Hematol"},{"key":"10.4065\/81.4.553_bib94","first-page":"59","article-title":"Excellent response to interferon therapy in a patient with hypereosinophilic syndrome and elevated serum immunoglobulin E levels","volume":"92","author":"Acaba","year":"2000","journal-title":"Bol Asoc Med P R"},{"key":"10.4065\/81.4.553_bib95","doi-asserted-by":"crossref","first-page":"716","DOI":"10.7326\/0003-4819-113-9-716","article-title":"Interferon-alpha for the hypereosinophilic syndrome","volume":"113","author":"Zielinski","year":"1990","journal-title":"Ann Intern Med"},{"key":"10.4065\/81.4.553_bib96","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1111\/j.1365-2141.1991.tb07993.x","article-title":"Alpha-interferon in a case of hypereosinophilic syndrome","volume":"77","author":"van den Anker-Lugtenburg","year":"1991","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib97","doi-asserted-by":"crossref","first-page":"338","DOI":"10.7326\/0003-4819-114-4-338_2","article-title":"Alpha-interferon for the hypereosinophilic syndrome","volume":"114","author":"Busch","year":"1991","journal-title":"Ann Intern Med"},{"key":"10.4065\/81.4.553_bib98","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/ajh.2830450311","article-title":"alpha-Interferon treatment for idiopathic hypereosinophilic syndrome","volume":"45","author":"Bockenstedt","year":"1994","journal-title":"Am J Hematol"},{"key":"10.4065\/81.4.553_bib99","doi-asserted-by":"crossref","first-page":"648","DOI":"10.7326\/0003-4819-121-9-199411010-00003","article-title":"Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome","volume":"121","author":"Butterfield","year":"1994","journal-title":"Ann Intern Med"},{"key":"10.4065\/81.4.553_bib100","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0091-6749(95)70043-9","article-title":"Effective long-term alpha-interferon treatment for hypereosinophilic syndrome","volume":"96","author":"Canonica","year":"1995","journal-title":"J Allergy Clin Immunol"},{"key":"10.4065\/81.4.553_bib101","doi-asserted-by":"crossref","first-page":"155","DOI":"10.7326\/0003-4819-123-2-199507150-00017","article-title":"Treatment of the hypereosinophilic syndrome with interferon-alpha","volume":"123","author":"Papo","year":"1995","journal-title":"Ann Intern Med"},{"key":"10.4065\/81.4.553_bib102","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1111\/j.1346-8138.2000.tb02131.x","article-title":"Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review","volume":"27","author":"Yoon","year":"2000","journal-title":"J Dermatol"},{"key":"10.4065\/81.4.553_bib103","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1177\/000331970205300414","article-title":"Favorable response to high-dose interferon-alpha in idiopathic hypereosinophilic syndrome with restrictive cardiomyopathy\u2014case report and literature review","volume":"53","author":"Baratta","year":"2002","journal-title":"Angiology"},{"key":"10.4065\/81.4.553_bib104","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1055\/s-2004-831852","article-title":"Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib [in German]","volume":"129","author":"Wolf","year":"2004","journal-title":"Dtsch Med Wochenschr"},{"key":"10.4065\/81.4.553_bib105","doi-asserted-by":"crossref","first-page":"2334","DOI":"10.1056\/NEJMoa031261","article-title":"Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis","volume":"349","author":"Plotz","year":"2003","journal-title":"N Engl J Med"},{"key":"10.4065\/81.4.553_bib106","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1016\/j.jaci.2004.08.027","article-title":"Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700","volume":"114","author":"Kim","year":"2004","journal-title":"J Allergy Clin Immunol"},{"key":"10.4065\/81.4.553_bib107","doi-asserted-by":"crossref","first-page":"2939","DOI":"10.1182\/blood-2003-10-3620","article-title":"Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome","volume":"103","author":"Klion","year":"2004","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib108","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/j.1365-2141.2004.05206.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome with abnormal T cells: a case report","volume":"127","author":"Pitini","year":"2004","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib109","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1046\/j.1365-2141.2003.04801.x","article-title":"Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome","volume":"124","author":"Sefcick","year":"2004","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib110","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1002\/ajh.2830270414","article-title":"Hypereosinophilic syndrome with multiple organ dysfunction treated by allogeneic bone marrow transplantation","volume":"27","author":"Archimbaud","year":"1988","journal-title":"Am J Hematol"},{"key":"10.4065\/81.4.553_bib111","first-page":"647","article-title":"Hypereosinophilic syndrome: successful allogeneic bone marrow transplantation","volume":"15","author":"Sigmund","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/81.4.553_bib112","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1111\/j.1365-2141.1995.tb03404.x","article-title":"Successful bone marrow transplantation for idiopathic hypereosinophilic syndrome","volume":"90","author":"Fukushima","year":"1995","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib113","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1002\/(SICI)1096-8652(199602)51:2<164::AID-AJH12>3.0.CO;2-I","article-title":"Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome","volume":"51","author":"Esteva-Lorenzo","year":"1996","journal-title":"Am J Hematol"},{"key":"10.4065\/81.4.553_bib114","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/sj.bmt.1700729","article-title":"Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis","volume":"19","author":"Sadoun","year":"1997","journal-title":"Bone Marrow Transplantation"},{"key":"10.4065\/81.4.553_bib115","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1038\/sj.bmt.1701783","article-title":"Allogeneic peripheral blood stem cell transplantation for hypereosinophilic syndrome with severe cardiac dysfunction","volume":"23","author":"Chockalingam","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/81.4.553_bib116","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/sj.bmt.1702102","article-title":"Allogeneic peripheral blood cell transplantation for hypereosinophilic syndrome with myelofibrosis","volume":"25","author":"Vazquez","year":"2000","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/81.4.553_bib117","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.bmt.1703379","article-title":"Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome","volume":"29","author":"Juvonen","year":"2002","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/81.4.553_bib118","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1046\/j.1365-2141.2002.03771.x","article-title":"Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome","volume":"119","author":"Ueno","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib119","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ajh.20214","article-title":"Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant","volume":"78","author":"Cooper","year":"2004","journal-title":"Am J Hematol"},{"key":"10.4065\/81.4.553_bib120","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1001\/archinte.1966.00290150019006","article-title":"Basophilic leukemia","volume":"118","author":"Kyle","year":"1966","journal-title":"Arch Intern Med"},{"key":"10.4065\/81.4.553_bib121","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1034\/j.1600-0609.2003.00086.x","article-title":"Chronic basophilic leukemia: a distinict clinico-pathologic entity?","volume":"71","author":"Pardanani","year":"2003","journal-title":"Eur J Haematol"},{"key":"10.4065\/81.4.553_bib122","first-page":"866","article-title":"Prognostic factors in myelodysplastic and myeloproliferative types of chronic myelomonocytic leukemia: a retrospective analysis of 83 patients from a single institution","volume":"89","author":"Breccia","year":"2004","journal-title":"Haematologica"},{"key":"10.4065\/81.4.553_bib123","first-page":"218","article-title":"Chronic myelomonocytic leukemia: myeloproliferative variant","volume":"3","author":"Onida","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"10.4065\/81.4.553_bib124","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1182\/blood.V99.3.840","article-title":"Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients","volume":"99","author":"Onida","year":"2002","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/0165-4608(86)90197-4","article-title":"Cytogenetics of chronic myelomonocytic leukemia","volume":"21","year":"1986","journal-title":"Cancer Genet Cytogenet"},{"key":"10.4065\/81.4.553_bib126","first-page":"408","article-title":"Sensitivity to imatinib but low frequency of the TEL\/PDGFRbeta fusion protein in chronic myelomonocytic leukemia","volume":"88","author":"Gunby","year":"2003","journal-title":"Haematologica"},{"key":"10.4065\/81.4.553_bib127","first-page":"109","article-title":"Cytogenetic clonality in chronic myelomonocytic leukemia studied with fluorescence in situ hybridization","volume":"9","author":"Fugazza","year":"1995","journal-title":"Leukemia"},{"key":"10.4065\/81.4.553_bib128","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/0165-4608(89)90071-X","article-title":"Cytogenetic analysis of different cellular populations in chronic myelomonocytic leukemia","volume":"37","author":"Cuneo","year":"1989","journal-title":"Cancer Genet Cytogenet"},{"key":"10.4065\/81.4.553_bib129","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2005-03-1183","article-title":"The JAK2 V617F activating tyrosine kinase mutation is an infrequent event in both \u201catypical\u201d myeloproliferative disorders and myelodysplastic syndromes","volume":"106","author":"Steensma","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib130","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1200\/JCO.1988.6.9.1417","article-title":"Prognostic factors in adult chronic myelomonocytic leukemia: an analysis of 107 cases","volume":"6","author":"Fenaux","year":"1988","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.4.553_bib131","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/S0145-2126(00)00078-3","article-title":"Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature","volume":"24","author":"Strupp","year":"2000","journal-title":"Leuk Res"},{"key":"10.4065\/81.4.553_bib132","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1159\/000040713","article-title":"Pleural effusion in chronic myelomonocytic leukemia","volume":"99","author":"Bourantas","year":"1998","journal-title":"Acta Haematologica"},{"key":"10.4065\/81.4.553_bib133","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1080\/1042819042000207271","article-title":"Risk assessment in chronic myelomonocytic leukemia (CMML)","volume":"45","author":"Germing","year":"2004","journal-title":"Leuk Lymphoma"},{"key":"10.4065\/81.4.553_bib134","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0025-6196(12)61287-7","article-title":"Chronic myelomonocytic leukemia: natural history and prognostic determinants","volume":"64","author":"Tefferi","year":"1989","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.4.553_bib135","doi-asserted-by":"crossref","first-page":"2480","DOI":"10.1182\/blood.V88.7.2480.bloodjournal8872480","article-title":"A randomized trial of hydroxyurea versus VP16 in adult chronic myelomonocytic leukemia","volume":"88","author":"Wattel","year":"1996","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib136","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3109\/10428199809057611","article-title":"Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"31","author":"Beran","year":"1998","journal-title":"Leuk Lymphoma"},{"key":"10.4065\/81.4.553_bib137","doi-asserted-by":"crossref","first-page":"2819","DOI":"10.1200\/JCO.1999.17.9.2819","article-title":"Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia","volume":"17","author":"Beran","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.4.553_bib138","first-page":"624a","article-title":"Chemotherapy of increasing intensity in the treatment of chronic myelomonocytic leukemia [abstract]","volume":"98","author":"Beran","year":"2001","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib139","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1046\/j.1365-2141.2002.03552.x","article-title":"Allogeneic stem cell transplantation of adult chronic myelomonocytic leukaemia: a report on behalf of the Chronic Leukaemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT)","volume":"118","author":"Kroger","year":"2002","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib140","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1182\/blood-2003-12-4207","article-title":"Reduced-intensity allogeneic hematopoietic stem cell transplantation for myelodysplastic syndrome and acute myeloid leukemia with multilineage dysplasia using fludarabine, busulphan, and alemtuzumab (FBC) conditioning","volume":"104","author":"Ho","year":"2004","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib141","first-page":"203","article-title":"Juvenile myelomonocytic leukemia","volume":"3","author":"Emanuel","year":"2004","journal-title":"Curr Hematol Rep"},{"key":"10.4065\/81.4.553_bib142","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/ng1156","article-title":"Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia","volume":"34","author":"Tartaglia","year":"2003","journal-title":"Nat Genet"},{"key":"10.4065\/81.4.553_bib143","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1182\/blood.V92.1.267.413a31_267_272","article-title":"Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1","volume":"92","author":"Side","year":"1998","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib144","doi-asserted-by":"crossref","first-page":"2325","DOI":"10.1182\/blood-2003-09-3287","article-title":"Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis","volume":"103","author":"Loh","year":"2004","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib145","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/sj.leu.2401240","article-title":"RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML)","volume":"13","author":"Flotho","year":"1999","journal-title":"Leukemia"},{"key":"10.4065\/81.4.553_bib146","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1182\/blood.V95.2.639","article-title":"Inhibition of juvenile myelomonocytic leukemia cell growth in vitro by farnesyl-transferase inhibitors","volume":"95","author":"Emanuel","year":"2000","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib147","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1182\/blood-2004-05-1944","article-title":"Hematopoietic stem cell transplantation (HSCT) in children with juvenile myelomonocytic leukemia (JMML): results of the EWOG-MDS\/EBMT trial","volume":"105","author":"Locatelli","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib148","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/sj.bmt.1704778","article-title":"Allogeneic bone marrow transplantation for juvenile myelomonocytic leukemia: a single center experience of 23 patients","volume":"35","author":"Korthof","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.4065\/81.4.553_bib149","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1097\/00005792-198811000-00001","article-title":"Systemic mast cell disease: analysis of 58 cases and literature review [published correction appears in Medicine (Baltimore). 1990;69:34]","volume":"67","author":"Travis","year":"1988","journal-title":"Medicine (Baltimore)"},{"key":"10.4065\/81.4.553_bib150","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/S0145-2126(01)00038-8","article-title":"Diagnostic criteria and classification of mastocytosis: a consensus proposal","volume":"25","author":"Valent","year":"2001","journal-title":"Leuk Res"},{"key":"10.4065\/81.4.553_bib151","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.4065\/77.11.1169","article-title":"Systemic mast cell disease without associated hematologic disorder: a combined retrospective and prospective study","volume":"77","author":"Pardanani","year":"2002","journal-title":"Mayo Clin Proc"},{"key":"10.4065\/81.4.553_bib152","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/0002-9343(91)90214-I","article-title":"Hematologic manifestations of systemic mast cell disease: a prospective study of laboratory and morphologic features and their relation to prognosis","volume":"91","author":"Lawrence","year":"1991","journal-title":"Am J Med"},{"key":"10.4065\/81.4.553_bib153","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S0145-2126(01)00102-3","article-title":"Immunohistochemical studies of c-kit, transforming growth factor-beta, and basic fibroblast growth factor in mast cell disease","volume":"26","author":"Baek","year":"2002","journal-title":"Leuk Res"},{"key":"10.4065\/81.4.553_bib154","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1016\/S0145-2126(01)00021-2","article-title":"Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings","volume":"25","author":"Horny","year":"2001","journal-title":"Leuk Res"},{"key":"10.4065\/81.4.553_bib155","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1046\/j.1365-2141.2003.04125.x","article-title":"Differential expression of CD2 on neoplastic mast cells in patients with systemic mast cell disease with and without an associated clonal haematological disorder","volume":"120","author":"Pardanani","year":"2003","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib156","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0002-9343(85)90454-1","article-title":"Comparison of the therapeutic efficacy of cromolyn sodium with that of combined chlorpheniramine and cimetidine in systemic mastocytosis: results of a double-blind clinical trial","volume":"78","author":"Frieri","year":"1985","journal-title":"Am J Med"},{"key":"10.4065\/81.4.553_bib157","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/0091-6749(83)90098-2","article-title":"Intervention with epinephrine in hypotension associated with mastocytosis","volume":"71","author":"Turk","year":"1983","journal-title":"J Allergy Clin Immunol"},{"key":"10.4065\/81.4.553_bib158","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1159\/000245681","article-title":"Short- and long-term effectiveness of oral and bath PUVA therapy in urticaria pigmentosa and systemic mastocytosis","volume":"195","author":"Godt","year":"1997","journal-title":"Dermatology"},{"key":"10.4065\/81.4.553_bib159","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1046\/j.1365-2796.1996.440787000.x","article-title":"Long-term follow-up of indolent mastocytosis in adults","volume":"239","author":"Kors","year":"1996","journal-title":"J Intern Med"},{"key":"10.4065\/81.4.553_bib160","doi-asserted-by":"crossref","first-page":"535","DOI":"10.1016\/S0140-6736(03)14115-3","article-title":"Imatinib for systemic mast-cell disease","volume":"362","author":"Pardanani","year":"2003","journal-title":"Lancet"},{"key":"10.4065\/81.4.553_bib161","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1200\/JCO.2001.19.11.2915","article-title":"BCR rearrangement-negative chronic myelogenous leukemia revisited","volume":"19","author":"Kurzrock","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.4065\/81.4.553_bib162","first-page":"149","article-title":"Clinical, morphological, cytogenetic and molecular aspects of a series of Ph-negative chronic myeloid leukemias","volume":"40","author":"Aurich","year":"1998","journal-title":"Hematol Cell Ther"},{"key":"10.4065\/81.4.553_bib163","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/j.1365-2141.1994.tb06734.x","article-title":"The chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia: proposals by the French-American-British Cooperative Leukaemia Group","volume":"87","author":"Bennett","year":"1994","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib164","first-page":"3","article-title":"The value of cell cultures for the diagnosis of mixed myelodysplastic\/myeloproliferative disorders","volume":"83","author":"Del Canizo","year":"1998","journal-title":"Haematologica"},{"key":"10.4065\/81.4.553_bib165","doi-asserted-by":"crossref","first-page":"2162","DOI":"10.1182\/blood-2005-03-1320","article-title":"Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders","volume":"106","author":"Jones","year":"2005","journal-title":"Blood"},{"key":"10.4065\/81.4.553_bib166","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1038\/nature03546","article-title":"A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera","volume":"434","author":"James","year":"2005","journal-title":"Nature"},{"key":"10.4065\/81.4.553_bib167","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1016\/S0140-6736(05)74230-6","article-title":"Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders","volume":"365","author":"Baxter","year":"2005","journal-title":"Lancet"},{"key":"10.4065\/81.4.553_bib168","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer Cell"},{"key":"10.4065\/81.4.553_bib169","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1056\/NEJMoa051113","article-title":"A gain-of-function mutation of JAK2 in myeloproliferative disorders","volume":"352","author":"Kralovics","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4065\/81.4.553_bib170","doi-asserted-by":"crossref","first-page":"22788","DOI":"10.1074\/jbc.C500138200","article-title":"Identification of an acquired JAK2 mutation in polycythemia vera","volume":"280","author":"Zhao","year":"2005","journal-title":"J Biol Chem"},{"key":"10.4065\/81.4.553_bib171","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1002\/cncr.21645","article-title":"The clinical phenotype of wild-type, heterozygous, and homozygous JAK2 (V617F) in polycythemia vera","volume":"106","author":"Tefferi","year":"2006","journal-title":"Cancer"},{"key":"10.4065\/81.4.553_bib172","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1111\/j.1365-2141.2005.05764.x","article-title":"JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance","volume":"131","author":"Wolanskyj","year":"2005","journal-title":"Br J Haematol"},{"key":"10.4065\/81.4.553_bib173","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1111\/j.1365-2141.2005.05776.x","article-title":"The JAK2 tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates","volume":"131","author":"Tefferi","year":"2005","journal-title":"Br J Haematol"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961161906X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002561961161906X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,15]],"date-time":"2020-05-15T01:19:56Z","timestamp":1589505596000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002561961161906X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4]]},"references-count":173,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2006,4]]}},"alternative-id":["S002561961161906X"],"URL":"https:\/\/doi.org\/10.4065\/81.4.553","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2006,4]]}}}